Recent News

• 03.05.2025 - Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
• 03.03.2025 - Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
• 02.26.2025 - Axsome Therapeutics to Participate in Upcoming Investor Conferences
• 02.24.2025 - Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
• 02.18.2025 - Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Recent Filings

• 03.03.2025 - 8-K Current report
• 03.03.2025 - EX-99.1 EX-99.1
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities